This morning we watched Albemarle rise 1.0% to a price of $241.5 per share. The large-cap Chemicals company is now trading -8.17% below its average target price of $262.98. Analysts have set target prices ranging from $155.0 to $360.0 per share for Albemarle, and have given the stock an average rating of buy.
The stock has an average amount of shares sold short at 6.4%, and a short ratio of 3.34. The company's insiders own 0.22% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 87.1% of Albemarle's shares being owned by this investor type.
Institutions Invested in Albemarle
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-03-31 | Vanguard Group, Inc. (The) | 12% | 14,204,830 | $3,430,466,445 |
| 2023-03-31 | Blackrock Inc. | 8% | 9,582,008 | $2,314,054,932 |
| 2023-03-31 | Capital International Investors | 8% | 9,450,054 | $2,282,188,041 |
| 2023-03-31 | State Street Corporation | 4% | 5,024,760 | $1,213,479,540 |
| 2023-03-31 | FMR, LLC | 3% | 3,026,254 | $730,840,341 |
| 2023-03-31 | Franklin Resources, Inc. | 2% | 2,731,009 | $659,538,673 |
| 2023-03-31 | Baillie Gifford and Company | 2% | 2,540,607 | $613,556,590 |
| 2023-03-31 | Capital Research Global Investors | 2% | 2,527,685 | $610,435,927 |
| 2023-03-31 | Geode Capital Management, LLC | 2% | 2,422,227 | $584,967,820 |
| 2023-03-31 | Bank of America Corporation | 2% | 2,043,164 | $493,424,106 |
Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Albemarle.
